Get started

Biotech

Pfizer (PFE) to continue its BULL run in 2022!Fundamental Analysis Pfizer, Inc. has consistently been one of the largest pharmaceutical companies in the world for the better part of the last two decades. The company has a remarkable history going back all the way to the year 1849, when Pfizer was founded in Brooklyn, New York. The large cap pharma giant has developed a well-balanced and deep portfolio of products in key areas like Inflammation and Immunology, Internal Medicine, Oncology, Rare Disease, Vaccines etc. However, it seems that as a result of the success of Pfizer's vaccine COVID-19 treatments, many investors have forgotten about the rest of Pfizer's business and how successful it continues to be. It is true that the sales of its COVID-19 vaccine ($36 billion in 2021 alone) have managed to nearly double Pfizer's annual revenue from $41.9 billion in 2020 to over $78 billion in 2021. What's even more important is that the strong sales growth has also translated into higher profits for the company as its profit margins before interest and taxes, referred to as EBIT margin, have risen over the past year. This shows that Pfizer has managed its R&D and all other fixed and operating costs associated with development, production and distribution efficiently, thus improving the profitability ratios of the company. The large cap pharma giant has also managed to almost triple the size of its free cash flow to more than $29 billion over the past twelve months compared to only $11.6 billion in 2020. More free cash flow makes a business more robust, giving Pfizer more money to invest in research and development of new products, pay more in dividends, or strengthen its balance sheet. The company currently has a total of 94 drugs in the pipeline spread across critical treatment areas like Inflammation and Immunology, Internal Medicine, Oncology, Rare Disease, Vaccines etc. all waiting regulatory approval. - Phase 1(27); Phase 2 (29); Phase 3 (29); Registration (9) Looking at the outstanding track record of Pfizer's drug development capabilities, we can easily state that the company will continue to be a leader in the sector that it operates in. Macro view The equity markets in the US are currently undergoing a process of meaningful repricing and re-valuation of what companies are actually worth, as everyone is getting ready for the Federal Reserve to start raising interest rates in the US and tighten its monetary policy. In a rising interest rate environment, investors tend to move away from expensive high-growth stocks trading at unreasonably high P/E and P/S valuations as the tighter monetary policy environment makes it much more difficult and more expensive for such companies to borrow and invest capital and produce the high earnings growth that investors expect from them. Well-established large cap Healthcare and Biotech stocks are considered to be least correlated with the monetary policy situation in the country as they tend to trade more on FDA drug approvals and drug-related announcements rather than actual earnings per share. Most of the leaders in this space also have a substantial pricing power, as people using their medicines are doing so because they need them and because the drugs are helping them get better. Thus, owning Healthcare and Biotech stocks in a rising inflation and interest rate environment is a defensive play that could end up paying off big time, as stocks in these sectors are rather volatile. Technical Analysis The stock has experienced a volatile retracement from its $61 all-time highs and is currently in a corrective phase. However, the uptrend is still intact as the price is well above both the strong horizontal support at $51 and the upward sloping diagonal support (blue line) at $44. Furthermore, the stock is trading above its 5, 20, 50, 200 EMAs, which is also a bullish continuation signal. We expect buyers to start coming in around the $52-53 level, thus establishing the next higher high. Once that is done, the stock will re-test its ATH at around $61 in Q1 of this year. The broad market framework, together with the many positive company related developments in the coming months are expected to bring enough momentum to the stock in order for it to break its previous ATH and set a new one sometime in Q2. Our target for the stock in H1 of 2022 is around the $68 level, which is roughly 30% higher from the current levels. Follow and Copy us on eToro for more detailed market analyses, profitable trading ideas and a consistent portfolio performance. [ b] Sincerely, @DowExperts
NYSE:PFELong
by DowExperts
$GNPX Target PTs 7 and higherGenprex Receives U.S. FDA Fast Track Designation for REQORSA™️ Immunogene Therapy in Combination With Keytruda®️ for the Treatment of Non-Small Cell Lung Cancer Second FDA Fast Track Designation Further Validates the Potential of REQORSA AUSTIN, Texas, January 03, 2022--(BUSINESS WIRE)--Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for the Company’s lead drug candidate, REQORSA™ Immunogene Therapy, in combination with Merck & Co’s Keytruda® in patients with histologically-confirmed unresectable stage III or IV non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Keytruda. In the first quarter of 2022, Genprex expects to initiate its Acclaim-2 clinical trial, which is an open-label, multi-center Phase 1/2 clinical trial evaluating REQORSA in combination with Keytruda, for this patient population. The Company previously received its first FTD for REQORSA in combination with AstraZeneca PLC’s Tagrisso® in patients with histologically confirmed unresectable stage III or IV NSCLC, with EGFR mutations that progressed after treatment with Tagrisso. "We are thrilled to receive a second Fast Track Designation from the FDA for REQORSA in patients with late-stage NSCLC, this time in combination with the checkpoint inhibitor Keytruda," said Rodney Varner, President and Chief Executive Officer at Genprex. "This Fast Track Designation is an important step in our efforts to accelerate clinical development of REQORSA and another validation of the potential of REQORSA to treat the unmet medical need of patients with late-stage NSCLC. With a strong balance sheet of $42 million in cash as of the end of the third quarter of 2021 and expert clinical trial management led by Chief Medical Officer and industry veteran Mark Berger, MD who joined Genprex in September 2021, we are well positioned to advance our Acclaim-1 and Acclaim-2 clinical trials in a meaningful way in 2022." Dr. Berger added, "Fast Track Designation provides a company opportunities to have more frequent engagement with the FDA to discuss the drug candidate’s development plan and also provides potential eligibility for priority review, which has a six-month review timeline. FDA may award Fast Track Designation if it determines that non-clinical or clinical data demonstrate the potential for a drug to address unmet medical need for a serious or life-threatening disease or condition. This provision is intended to facilitate development and expedite review of such drugs so that a product, if approved, can reach the market expeditiously. Advanced NSCLC represents a large patient population that is in desperate need of new therapies." Previously presented preclinical data have shown synergy between REQORSA and Keytruda. Those data showed that REQORSA combined with Keytruda was more effective than Keytruda alone in increasing the survival of mice with a humanized immune system that had metastatic lung cancers. Those studies in mice with a humanized immune system also documented multiple effects of REQORSA on the immune system, such as an increase in Natural Killer cells and a decrease in PD-L1 expression on tumor cells, that is believed likely to contribute to the synergy seen with Keytruda. Fast Track Designation recipients may also be eligible for accelerated approval or rolling review of the recipient’s Biologics License Application (BLA) if other qualifying criteria are met. In addition, Fast Track product candidates could be eligible for priority review if supported by clinical data at the time of BLA submission. The initial intended disease indication for development of REQORSA is NSCLC. According to the World Health Organization, in 2020 lung cancer was the leading cause of cancer deaths worldwide, causing more deaths than colorectal, breast, liver or stomach cancers. There were more than 2 million new lung cancer cases and 1.8 million deaths from lung cancer worldwide. In the United States, according to the American Cancer Society, it is estimated that in 2021, there will be more than 235,000 new cases of lung cancer and more than 131,000 deaths from lung cancer. The American Society of Clinical Oncology reports that NSCLC represents 84 percent of all lung cancers and the five-year survival rate for patients with NSCLC with distant spread is 7 percent. For more information on the U.S. FDA’s Fast Track Designation, please visit the FDA’s Fast Track webpage. About Genprex, Inc. Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its unique, proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is then taken up by tumor cells that express proteins that are deficient. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with AstraZeneca’s Tagrisso® (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso.
NASDAQ:GNPXLong
by BADQOMOCAWGOWLD
$XBI - Fundamentally Undervalued, Strong Bounce Off Of SupportI posted the wrong chart when doing my analysis on this ticker last time, so I'm here to update my error! This is a very interesting sector to keep an eye on after it's gotten relentlessly hammered for the past six months. There are now over 100 biotech stocks selling below cash, meaning these companies literally have more cash on their balance sheet than their entire market cap! Furthermore, there are 300 additional biotech stocks selling at 1/2 cash (50% of their balance sheet is at least half of their current market cap). There are an insane amount of bargains within this sector, and the entire sector is poised to make a reversal after a strong bounce off of support, and bullish engulfing candle on the daily. I wouldn't be surprised to see this entire batch of stocks start to perform very well over the following months. A trip back to the 130s is almost inevitable.
AMEX:XBILong
by FluxTrades
3
NUMI 1000% move potential - are you in?This daily chart is a beauty setup. Just listed today December 16th on the TSX (graduated from the TSXV) and far undervalued compared to its peers. Bonus facts: - Health Canada licenses, some exclusive - Strong influencer on regulatory market - Multiple successful clinical trials - NO DEBT - and a warchest full of cash - Some big acquisitions this year, becoming a corporate umbrella with multiple lines of business - Awesome Management team - Well managed financials Need I say more? Get this gem before everyone else finds out about it. Likely to follow MMED.
NEO:NUMILong
by Shadowfigure
$ARCT is a BUY nowArcturus Therapeutics Holdings Inc. $ARCT is set to be EBITDA positive in 2022 with a massive change in its revenue from 24.05M in 2021 to 326.44M in 2022. This is 12.57x increase in revenue. These numbers are estimates, but even with a large error margin we should see a drastic change in the price. Moreover, the decline from ATH was 80% and the price has been in a sideways movement after it bottomed. With today's strong breakout of the descending channel, I am expecting the price to start its rise up to the upper band of the range-bound around $63. The long-term targets should be a lot higher. The breakout setup entry provides us with an awesome +3 Reward/Risk. A tighter stop loss order can even make it a lot better. A late entry at current prices provides 1.8-2.0 which is still a good ratio. BioTech stocks are risky and volatile. This is not financial advice. DYODD
NASDAQ:ARCTLong
by IboProtrader
Looking for a long term entry into Globus MedicalI’m looking for a long term investment in a sea of overvalued bio & tech companies. Globus Medical caught my eye as a potential candidate after a large dark pool sell and recent pullback in indexes Globus Medical's index membership is Russell 1000, Russell 3000 and S&P Midcap 400. Financial Observations: PE ratio of 37 a return to 2017 levels. 7B Market Cap Consistent Year over Year revenue growth. Nominal Debt Exceeds earnings expectations Steady asset growth Regular employment growth Personal Experience A surgical clinic I do marketing and websites for recently added one of the Globus Medical robot arm surgical assistants. The chief surgeon told me his surgery averages went from 1hr to 10m. The client has also made it a priority for us to increase marketing spend and patient intake support to increase daily surgery capacity. I’m curious to know what the more seasoned investors think of GMED and if this is a good time to make an entry for a long term holding. Not Financial Advice. Just my own Personal Investment Due Diligence.
NYSE:GMEDLong
by SPYvsGME
1
$Enzc where do we go from here??? The chart broke down from our previous wedge, causing a wide broadening formation. We broke below the 0.618 fib level, would have liked to see a sustained volume shelf there creating a better support. Price will need to bounce from 0.1011 and close above that level or we will continue to see continued selling pressure. EXPECT ALOT OF VOLATILITY FOR THE REMAINDER OF DECEMBER! I still haven't sold a single share and will continue to aquire more every chance I get (seems more now than ever) Know your 50/30/20 rule! 50% of what a stock does is determined by what the overall market does 30% of what a stock does is determined by what the sector & industry group does 20% of the movement of the stock is determined by the analysis of the stock itself
OTC:ENZC
by OptionStonker
Record financials warrant a re-ratingQ3 2021 results warrant a re-rating of this $30M mkt cap biotech play: - Revenue was $25.3 million in the third quarter of 2021, up 575%, compared to $3.7 million over the prior three-month period ending June 30, 2021. - Gross profit was $10.5 million in the third quarter of 2021, up 1,288%, compared to $753,535 over the prior three-month period ending June 30, 2021. - Net income was $6.8 million in the third quarter of 2021, compared to a net loss of $8.7 million over the prior three-month period ending June 30, 2021.
MLong
by wealth_bakery
3
$BFRI entry PT 6 Target PT 11-20 and higherNote: ER 11/30 Tues Roth Capital analyst Jonathan Aschoff initiated coverage of BFRI stock with a buy rating and $20 price target. The analyst believes the stock is poised for growth thanks to its U.S. sales plans. Biofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy. The company was founded in 1997 and is based in Woburn, Massachusetts.
NASDAQ:BFRILong
by BADQOMOCAWGOWLD
$LGVN entry PT 25 Target PTs 43-49 and higherLongeveron stock is up by a multiple of 11 after the FDA gave a Rare Pediatric Disease designation for a heart medication last week. Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
NASDAQ:LGVNLong
by BADQOMOCAWGOWLD
1
$ISPC entry 14.65-16.15-ish Target PTs 29 and higheriSpecimen, Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables researchers to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
NASDAQ:ISPCLong
by BADQOMOCAWGOWLD
1
Big Pharma Holds the LineLast week ended with sell-offs amid fears about the new extremely contagious COVID 19 Omicron variant. Crude and stock markets suffered. But during this brief rally some shares continued to gain, and it is no wonder that these are the stocks of vaccine producers. Pfizer stocks posted a new all-time high on Friday rising by 6.11% to $54.94. Stocks were additionally supported when the company promised to develop a tailor-made vaccine in 100 days if the Omicron variant cannot be tamed by the current vaccine. The shares also reacted to the news that the European Medicines Agency approved the BioNTech-Pfizer vaccine for children aged 5-11. That is good news for the world’s top-selling medicine of the year. In order for the shares to continue on this upside climb, the price of Pfizer stocks need to remain above $50.49, which is the shares’ peak which was reached in August, and also keep with its upward trend that started on November 4 and has a support level at $51.50-51.80. BioNTech stocks also performed well, adding some 14.19% on Friday. The technical picture suggests stocks may rise further as they managed to break through the downward channel they have been on since August 10. Besides, we may see a reverse pattern “double dip” with a neck level crossing $304.35. The implementation of this pattern may boost stock prices to $378.67-401.19. Stock prices are close to the 61.8% Fibonacci correction level of the lows of August-November at $365.13. In case this landmark is passed, investors will have more reasons to push the stock to this year’s highs. Moderna stocks also enjoyed the sunny side of the COVID-19 panic as they soared by 20.57% to $329.63 on Friday, breaking from their downward channel which began on September 23. The next price target is at the $387-395 area, where the 61.8% Fibonacci level from the downside correction of August-November, and the resistance line of the downward trend from August 10 are located. I have already said that all Big Pharma stocks should be included in portfolios as they may all rally. Nevertheless, at the beginning of the new week fears around the South African Omicron variant have faded as the virologist Barry Schoub, who advises the South African government, said he did not believe the variant will lead to a major new wave of serious illness and the vaccine will still protect most people from severe cases of COVID-19. But the overall picture now that there is a new variant in circulation is unclear, and the market may become agitated. In this case the best option is to have downside-resistant stocks in your portfolio. Some people may find profit anywhere!
NASDAQ:MRNALong
by scavoanastasiia
$BFRIBiofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy. The company was founded in 1997 and is based in Woburn, Massachusetts.
NASDAQ:BFRILong
by BADQOMOCAWGOWLD
$MRNAModerna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, Metagenomi, Inc., and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd.; Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group; Aldevron, LLC; Institute for Life Changing Medicines; and AbCellera Biologics Inc. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
NASDAQ:MRNALong
by BADQOMOCAWGOWLD
$APVOAptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It is also developing APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer; and other pre-clinical development stage therapeutics focused on hematologic and solid tumors. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
NASDAQ:APVOLong
by BADQOMOCAWGOWLD
1
$QLGNQualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California.
NASDAQ:QLGNLong
by BADQOMOCAWGOWLD
4
🔴 Analysis of biotech with great potentialIn this post I analyzed one interesting biotech Endo International. Endo is a global pharmaceutical corporation headquartered in Dublin (legal) and Malvern, PA (operating). It was created in 1997 on a joint basis with DuPont Merck. Among the areas of drug development: immunotherapy, dermatology, infectious diseases, insomnia, orthopedics, urology, cellulite, oncology, endocrinology. The company also manufactures pain relievers and equipment needed to diagnose various diseases. Revenue for 2020 is $ 2.9 billion, profit is $ 0.25 million. Capitalization is $ 1.4 billion. Employees 3172. The company's business is represented by 4 areas: 1. Endo Pharmaceuticals develops unique products from scratch. At the moment, this direction has 16 commercial drugs. There are only 2 drugs in development. 2. Par Pharmaceuticals produces generic (copies) pharmaceuticals. This company was acquired by the American company Endo Pharmaceuticals in 2015 for $ 8.05 billion. This deal allowed Endo to become one of the five largest manufacturers of generics in the United States. Par Pharmaceuticals manufactures about 140 drugs. 3. Endo Aesthetics develops solutions for the treatment of cellulite. 4. Paladin Labs specializes in the acquisition and licensing of new pharmaceutical products for the Canadian market, and also manufactures products for the treatment of allergies, urological and dermatological diseases, diseases of the central nervous system and women's health. The company was acquired by Endo Pharmaceuticals in 2013 for $ 1.6 billion to gain access to the Canadian market and expand into emerging markets. Endo reached its peak value in 2015, then $ 90 was given per share. This was followed by a collapse in prices amid accusations of the "opioid epidemic" that began in the United States in the late 90s and lasted until 2016. This term refers to a large number of abuse and fatal overdoses of drugs that contain opiates. Authorities estimate that more than 450,000 Americans have died from opioids in 17 years. Purdue Pharma was identified as the main culprit. However, lawsuits were brought against other corporations as well. Endo has been identified as one of the culprits in the epidemic in 3 states: Ohio, Missouri and Mississippi. In 2016, most of the company's revenues were generated precisely from the sale of opioid-based painkillers. On November 2, an Orange County Supreme Court judge issued a preliminary ruling that relieves the company of responsibility for fueling the opioid epidemic in the United States. On this day, quotes added almost 10%. In 2020, Endo, for the first time in many years, made a profit of $ 184 million. Prior to that, for several years in a row, it managed to reduce losses, which in 2017 exceeded $ 2 billion. In general, the company's revenue is stagnating, the company is teetering on the brink of break-even. An interesting fact: the company for 30 quarters in a row manages to show financial indicators better than analysts' forecasts (in the pharmaceutical industry this is rarely seen). On November 4, the report for the third quarter was released. The published figures significantly exceeded analysts' estimates. On November 5, quotes added 25%. 🔧In terms of technique, the graph looks towards the short: 1) The price approached a strong weekly level. 2) Closing of the daily and weekly candles near the level and under the very LOW. 3) The price has broken the local level of $ 6.24 4) There is a large power reserve at the bottom. 5) Pulling the local maximum to the level, they are not allowed to go up. 6) Accumulation before the level. 7) Parabolic rounding. 8) Recoilless movement over 250%. Breakout of the local level $ 6.14 The price is likely to consolidate in the $ 6.15 - $ 6.50 channel with false breakouts of the support level before starting a correction. Be careful. Goal 1: $ 5.3 Target 2 (risk): $ 3.5 (more than 40% of the movement) NOT IRR.
EShort
by Trader_Ivankov
2
$PROGProgenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
PLong
by BADQOMOCAWGOWLD
$LGVNLongeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
NASDAQ:LGVNLong
by BADQOMOCAWGOWLD
3
$KZR Long term PT 35 and higherKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is based in South San Francisco, California.
NASDAQ:KZRLong
by BADQOMOCAWGOWLD